

Lista Publicatii-ISI

1. **S Avram**, Puia A, Udrea A M, Mihailescu D, Mernea M, Oancea F, Dinischiotu A and Stiens J, 2020, Natural compounds therapeutic features in brain disorders by experimental, bioinformatics and cheminformatics methods, Current Medicinal Chemistry, Volume 27, Number 1, 2020, pp. 78-98(21).
2. Bordei Telehoiu AT, Nuță DC, Căproiu MT, Dumitrascu F, Zarafu I, Ioniță P, Bădiceanu CD, **S Avram**, Chifiriuc MC, Bleotu C, Limban C. Design, Synthesis and In Vitro Characterization of Novel Antimicrobial Agents Based on 6-Chloro-9*H*-carbazol Derivatives and 1,3,4-Oxadiazole Scaffolds. Molecules. 2020 Jan 9;25(2):266.
3. N Guma, A Nastase, **S Avram**, R Buzatu, Bioinformatics and Cheminformatics Tools Applied to Chitosan and Derivatives with Biomedical Applicability, Rev. Chim., 71 (5), 2020, 157-162.
4. N Guma, A Nastase, M Motoc, **S Avram**, Bioinformatics Study Applied to the Pharmacokinetic Profile of Chitosan and its Derivatives with Biomedical Applicability, Rev. Chim., 71 (6), 2020, 261-266.
5. Vlad IM, Nuta DC, Chirita C, Caproiu MT, Draghici C, Dumitrascu F, Bleotu C, **S, Avram** Udrea AM, Missir AV, Marutescu LG, Limban C, In Silico and In Vitro Experimental Studies of New Dibenz[*b,e*]oxepin-11(6*H*)one O-(arylcarbamoyl)-oximes Designed as Potential Antimicrobial Agents. Molecules. 2020 Jan 13;25(2):321. doi: 10.3390/molecules25020321.
6. **Avram S**, Mernea M, Limban C, Borcan F, Chifiriuc C, Potential Therapeutic Approaches to Alzheimer's Disease by bioinformatics, cheminformatics and predicted ADME-Tox tools. Current Neuropharmacology. 2019 Dec 30. doi: 10.2174/1570159X186661912301200.
7. Limban, C, Dițu, L M, Măruțescu L, Missir A V, Chifiriuc M C, Căproiu M T, Morusciag L, Chiriță C, Udrea A-M, Nuță D C, **S Avram** , Design, Synthesis and Biopharmacological Profile Evaluation of New 2-((4-Chlorophenoxy)Methyl)-N-(Arylcarbamothioyl)Benzamides with Broad Spectrum Antifungal Activity, Current Organic Chemistry, Volume 23, Number 12, 2019, pp. 1365-1377(13).
8. **S Avram**, AM Udrea, A Negrea, M Ciopec, N Duteanu, C Postolache, C Duda-Seiman, D Duda-Seiman, S Shaposhnikov, 2019, Prevention of Deficit in Neuropsychiatric Disorders through Monitoring of Arsenic and Its Derivatives as Well as Through Bioinformatics and Cheminformatics., Int J Mol Sci. Apr 12;20(8). pii: E1804. doi: 10.3390/ijms2008180
9. I. Vlaicu, R. Olar, C. Maxim, M. C. Chifiriuc, C. Bleotu, N. Stănică, G. Scăețeanu, C. Dulea, **S. Avram**, M. Badea, 2019, Evaluating the biological potential of some new cobalt (II) complexes with acrylate and benzimidazole derivatives, Applied Organometallic Chemistry, <https://doi.org/10.1002/aoc.4976>
10. A.M. Udrea, A. Puia, S. Shaposhnikov **S. Avram**, 2018, Computational approaches of new perspectives in the treatment of depression during pregnancy, Farmacia, 66(4), 680-687.
11. D. Duda Seiman, A Batalu, C. Duda Seiman, M. Ciopec, A. M. Udrea, M. Motoc, A. Negrea, **S Avram**, 2018, Pharmacological Effects of Natural Compounds Extracted from Urtica dioica Evaluated by in Silico and Experimental Methods, REV.CHIM.(Bucharest), 69 (9), 2377-2381,
12. **Avram S**, Milac A, Borcan L-C, Mihailescu D, Borcan F and Castanho M, 2018, Designing of Artificial Peptides for an Improved Antiviral Activity, Current Proteomics, 15, 258-266.
13. **Avram S**, Alexandrescu I, Puia A, Udrea A M., Mernea M, Mihailescu D F, Borcan L-C, 2017, Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi

Terminal Domain Analyzed by SAR and Computational Mutagenesis, *Current Proteomics*, 14, 254-260.

14. **Avram, S.**, Mernea M, Bagci, E, Hritcu, L, Borcan L-Cr, Mihailescu Dan F., 2017, Advanced Structure-activity Relationships Applied to *Mentha spicata* L. Subsp. *spicata* Essential Oil Compounds as AChE and NMDA Ligands, in Comparison with Donepezil, Galantamine and Memantine – New Approach in Brain Disorders Pharmacology, CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), 16(7), 800-811.
15. Buiu C., Putz M.V., **Avram S.**, 2016, Learning the relationship between the primary structure of HIV envelope glycoproteins and neutralization activity of particular antibodies by using artificial neural networks, *Int J Mol Sci.*, 17(10): 1710.
16. Putz MV, Duda-Seiman C, Duda-Seiman D, Putz AM, Alexandrescu I, Mernea M, **Avram S.**, 2016, Chemical Structure-Biological Activity Models for Pharmacophores' 3D-Interactions, *Int J Mol Sci.* 17(7). pii: E1087. doi: 10.3390/ijms17071087.
17. Mernea M, Borcan L.C., Borcan F and **Avram S.**, 2016, Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies, *Letter in Drug Design and Discovery* 13(4): 269 – 275.
18. **Avram S.**, Mernea M, Borcan F, Mihailescu D. 2016, Evaluation of the Therapeutic Properties of Mastoparan- and Sifuvirtide- Derivative Antimicrobial Peptides Using Chemical Structure-Function Relationship - in vivo and in silico Approaches. *Curr Drug Deliv.* 13(2):202-210.
19. O. Grigore, O. Calborean, G. Cojocar R. Ungureanu M. Mernea M.P. Dinca, **Avram S.** D.F. Mihailescu T. Dascalu, High-intensity THz pulses application to protein conformational changes, *Romanian Reports in Physics*, Vol. 67, No. 4, P. 1251–1260, 2015.
20. **Avram S.**, Borcan F, Borcan LC, Milac AL, Mihailescu D. 2015, QSAR Approaches Applied to Antidepressants Induced Neurogenesis - in vivo and in silico Applications. *Mini Rev Med Chem.* 2016;16(3):230-40.
21. **Avram S.**, Mernea M., Mihailescu D., Duda Seiman C., Duda Seiman D., Putz M. 2014, Mitotic checkpoint proteins Mad1 and Mad2 – Structural and functional relationship with implication in genetic diseases. *Current Computer Aided Drug Design*, 10(2), 168-181.
22. **Avram S.**, Shaposhnikov S., Buiu C., Mernea M. 2014, Chondroitin Sulfate Proteoglycans: Structure-Function Relationship with Implication in Neural Development and Brain Disorders, *BioMed Research International*, Article ID 642798, 1-11, <http://dx.doi.org/10.1155/2014/642798>.. Epub 2014 May 14.
23. **Avram S.**, Milac A., Mernea M., Mihailescu D., Putz M.V., Buiu C. 2014, Structure-biological function relationship extended to mitotic arrest-deficient 2-like protein mad2 native and mutants-new opportunity for genetic disorder control. *Int. J. Mol. Sci.* 15(11), 21381-21400.
24. **Avram S.**, Buiu C., Milac A., Duda Seiman D., Duda Seiman C., Pacureanu L., Borcan F. 2014, More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods, *Current Computer Aided Drug Design*, 10(3), ISSN 1875-6697 .
25. Crisan L. E., Pacureanu L., Avram S. I., Bora A. M., **Avram S.**, Kurunczi L. 2014, PLS and shape-based similarity analysis of maleimides - GSK-3 inhibitors. *Journal Of Enzyme Inhibition And Medicinal Chemistry*, 29(4), 599-610.
26. **Avram S.**, Milac A., Carta F., Supuran C. T. 2013. More effective dithiocarbamates derivatives inhibiting carbonic anhydrases, generated by QSAR and computational design. *Journal Of Enzyme Inhibition And Medicinal Chemistry*, 28(2), 350-359.

27. **Avram S.**, Mernea M., Mihailescu D., Duda Seiman D., Duda Seiman C. 2013. Advanced QSAR methods evaluated polycyclic aromatic compounds duality as drugs and inductors in psychiatric disorders. *Current Organic Chemistry*, 17(23), 2880-2890.
28. Calborean O., Mernea M., **Avram S.**, Mihailescu D. F., 2013. Pharmacological descriptors related to the binding of gp120 to CD4 corresponding to 60 representative HIV-1 Strains. *Journal Of Enzyme Inhibition And Medicinal Chemistry*, 28(5), 1015-1025.
29. **Avram S.**, Mihailescu D., Milac A.L., 2012. 3D-QSAR study indicates an enhancing effect of membrane ions on psychiatric drugs targeting serotonin receptor 5-HT1A. *Molecular Biosystems*, 8 (5), 1418 – 1425.
30. **Avram S.**, Mihailescu D., Borcan F., Milac A.L. 2012. Prediction of improved antimicrobial mastoparan derivatives by 3D-QSARCoMSIA/CoMFA and computational mutagenesis. *Monthly Chemistry*, 143 (4), 535-543.
31. **Avram S.**, Buiu C., Borcan F., Milac A., 2012. More effective antimicrobial mastoparan derivatives, generated by 3D-QSAR-Almond and computational mutagenesis. *Molecular Biosystems*, , 8 (2), 587–594.
32. **Avram S.**, Buiu C., Duda-Seiman D., Borcan F., Duda-Seiman C., Mihailescu D. 2012. Evaluation of the pharmacological descriptors related to the induction of antidepressant activity and its prediction by QSAR/QRAR methods. *Mini Reviews in Medicinal Chemistry*, 12(6), 467-476.
33. **Avram S.**, Duda-Seiman D., Borcan F., Radu B., Duda-Seiman C., Mihailescu D. 2011. Evaluation of antimicrobial activity of new mastoparan derivatives using QSAR and computational mutagenesis, *International Journal of Peptide Research and Therapeutics*, 17(1), 7-17.
34. Lazlo T., **Avram S.**, Mihailescu D., 2011. QSAR study on biochemical activity of some escitalopram derivatives with possible antidepressant activity. *Rev. Chim. (Bucharest)*, 62 (4), 371-375.
35. **Avram S.**, Duda-Seiman D., Borcan F., Wolschann P. 2011. QSAR-CoMSIA applied to antipsychotic drugs with their dopamine D2 and serotonin 5HT2A membrane receptors. *Journal of the Serbian Chemical Society*, 76 (2), 263-281.
36. Duda-Seiman D, **Avram S.**, Mancaş S., Careja V., Duda-Seiman C., Putz M. V., Ciubotariu D. 2011. MTD-CoMSIA Modelling of HMG-CoA Reductase Inhibitors. *Journal of the Serbian Chemical Society*, 76 (1), 85-99.
37. **Avram S.**, Duda-Seiman D., Duda-Seiman C., Borcan F., Mihailescu D. 2010. Predicted binding rate of new cephalosporin antibiotics by 3D-QSAR- method – new approach. *Monthly Chemistry*, 141(5), 589-597.
38. **Avram S.**, Buiu C., Duda-Seiman D., Duda-Seiman C., Mihailescu D. 2010. Design of new escitalopram derivatives for the treatment of major depressive disorder by 3D-QSAR. *Sci Pharm.*, 78(2), 233–248.
39. **Avram S.**, Duda-Seiman D., Svab I., Mancaş S., Duda-Seiman C., Mihailescu D. 2009. Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives, *Current Computer-Aided Drug Design*, 5(1), 1-12.
40. **Avram S.**, Berner H., Milac A.L., Wolschann P. 2008. Quantitative structure – activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment. *Monthly Chemistry*, 139 (4), 407-426.

41. Milac A.L., **Avram S.**, Petrescu A.J. 2006, Evaluation of a neural networks QSAR method based on ligand representation using substituent descriptors. Application to HIV-1 protease inhibitors, *Journal of Molecular Graphics and Modelling*, , 25(1), 37-45.
42. **Avram S.**, Bologa C., Flonta M.L. 2005, Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptidecyclic cyanoguanidine derivatives on the wild type and mutants HIV-1 protease. *J.Mol .Modeling*, 11(2), 105-115.
43. **Avram S.**, Milac A.L., Flonta M.L. 2005, Computer-aided drug design for typical and atypical antipsychotic drugs. A review of application of QSAR and combinatorial chemistry methods-tools for new antipsychotics design. *Current Computer-Aided Drug Design*,1(4), 347-364.
44. **Avram S.**, Svab I., Bologa C., Flonta M.L., 2003, Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors by 3D-QSAR-CoMFA method – a tool for new antiviral drugs design, *Journal of Cellular and Molecular Medicine*, 7(3), 287-296.
45. **Avram S.**, Movileanu L., Mihailescu D., Flonta M.L., 2002, Comparative study of some energetic and steric parameters of the wild type and mutants HIV-1 protease: a way to explain the viral resistance, *Journal of Cellular and Molecular Medicine*, 6,(2), 251-260.

Prof. Dr. Speranta Avram

